Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas

Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
V K MehtaJ A Bastidas

Abstract

Only 10% to 20% of patients with pancreatic cancer are considered candidates for curative resection at the time of diagnosis. We postulated that preoperative chemoradiation therapy might promote tumor regression, eradicate nodal metastases, and allow for definitive surgical resection in marginally resectable patients. The objective of this study was to evaluate the effect of a preoperative chemoradiation therapy regimen on tumor response, resectability, and local control among patients with marginally resectable adenocarcinoma of the pancreas and to report potential treatment-related toxicity. Patients with marginally resectable adenocarcinoma of the pancreas (defined as portal vein, superior mesenteric vein, or artery involvement) were eligible for this protocol. Patients received 50.4 to 56 Gy in 1.8 to 2.0 Gy/day fractions with concurrent protracted venous infusion of 5-fluorouracil (250 mg/m2/day). Reevaluation for surgical resection occurred 4 to 6 weeks after therapy. Fifteen patients (9 men and 6 women) completed preoperative chemoradiation without interruption. One patient required a reduction in the dosage of 5-fluorouracil because of stomatitis. Acute toxicity from chemoradiation consisted of grade 1 or 2 nausea, vomi...Continue Reading

Citations

Mar 11, 2005·Abdominal Imaging·G KarmazanovskyA Kotchatkov
Sep 25, 2008·Cancer Control : Journal of the Moffitt Cancer Center·Gregory M Springett, Sarah E Hoffe
Jul 19, 2013·HPB Surgery : a World Journal of Hepatic, Pancreatic and Biliary Surgery·Hui JiangHong Wu
Jun 25, 2013·Current Treatment Options in Oncology·Amanda B CooperMatthew H G Katz
Aug 26, 2014·World Journal of Gastroenterology : WJG·Nicole E LopezAndrew M Lowy
Jun 24, 2017·International Journal of Molecular Sciences·Aleksandra AdamskaMarco Falasca
Dec 30, 2017·Abdominal Radiology·David R Fogelman, Gauri Varadhachary
Jul 30, 2020·Current Treatment Options in Oncology·Giampaolo PerriMatthew H G Katz
Nov 29, 2012·The Cancer Journal·Stephanie L Goff, John A Chabot
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher H CraneRobert A Wolff
Jan 8, 2011·Annals of Surgical Oncology·Jayme B StokesTodd W Bauer
Mar 6, 2010·The Oncologist·Rajarshi Roy, Anthony Maraveyas
Apr 27, 2011·Journal of Surgical Oncology·Manish PatelGregory Springett
May 4, 2015·Journal of Hematology & Oncology·Gaurav Goel, Weijing Sun
Jan 18, 2018·Japanese Journal of Clinical Oncology·Shinichiro Takahashi
Feb 22, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Matthew D JohnsonGeorge D Wilson
May 7, 2019·World Journal of Gastrointestinal Surgery·Kemal DolaySami Akbulut
Feb 23, 2020·Frontiers in Oncology·Quisette P JanssenBas Groot Koerkamp
Aug 15, 2019·Journal of Clinical Medicine·Morgan Bonds, Flavio G Rocha
Jan 5, 2002·Expert Opinion on Investigational Drugs·Conor J MageeJohn P Neoptolemos
Jan 22, 2014·Current Oncology Reports·Daniel M Halperin, Gauri R Varadhachary
Sep 28, 2017·Abdominal Radiology·Annabelle L Fonseca, Jason B Fleming
Apr 16, 2005·The Cancer Journal·Daniel TsengJohn G Hunter
Nov 21, 2020·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Daniel L P HolyoakeMaria A Hawkins
Apr 14, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J W GilbertM Rosenthal
May 7, 2021·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Asanka R WijetungaJaswinder S Samra
Jul 24, 2021·Indian Journal of Surgical Oncology·Kailash Chand Kurdia, Vinay K Kapoor
May 30, 2007·Gastroenterology Clinics of North America·Jan FrankoA James Moser
Dec 2, 2017·The Surgical Clinics of North America·Robert A Wolff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.